Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Pfizer buys Seagen for 43B$
View:
Comment by ScienceFirst on Mar 13, 2023 8:43am
  Pfizer will pay $229 in cash per Seagen share, a 32.7% premium to Friday's closing price. The offer is also a nearly 42% premium to the stock's close on Feb. 24, a day before the Wall Street Journal first reported on a possible deal.     Pfizer has hit the deals route in its quest to mitigate the impact from an anticipated $17 billion drop in revenue by 2030 due to ...more  
Comment by 99942Apophis on Mar 13, 2023 5:51pm
I think many of TLT shareholders had eyes on this one, Pfizer looks like a giant roller in action. My guess is if BTD does come through with an improved CR then it will be down to both Merck and Pfizer fighting it out to partner with Theralase. Of course a buyout could top Seagens deal in my biased opinion. 
Comment by ScienceFirst on Mar 13, 2023 6:38pm
    Seagen, long considered one of the world’s most attractive biotech targets, brings four commercial medicines and a deep pipeline full of antibody-drug conjugate (ADC) candidates. The company hit $2 billion in revenue last year, a 25% increase from 2021. Pfizer said that it expects the products brought by Seagen to bring $10 billion in annual revenues by 2030 ...more